Monopar Therapeutics Inc. Tax Withholding Paid on Stock Awards
Monopar Therapeutics Inc. (MNPR) reported Tax Withholding Paid on Stock Awards of $855.17 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-12
- Monopar Therapeutics Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $654.96K, a 103.69% increase year-over-year.
- Monopar Therapeutics Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $200.20K, a 52.68% increase year-over-year.
- Monopar Therapeutics Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $298.09K, a 345.28% increase year-over-year.
- Monopar Therapeutics Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $381.56K, a 2207.75% increase year-over-year.
- Monopar Therapeutics Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $1.13M, a 986.49% increase from fiscal 2024.
- Monopar Therapeutics Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $104.22K, a 121.89% increase from fiscal 2023.
- Monopar Therapeutics Inc. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $46.97K, a 38.71% decline from fiscal 2022.
- Monopar Therapeutics Inc. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $76.63K.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $654.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $855.17K 10-Q · filed 2026-08-12 | $1.15M derived: sum of 3 quarters · filed 2026-08-12 | $1.53M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $200.20K 10-Q · filed 2026-05-14 | $498.30K derived: sum of 2 quarters · filed 2026-05-14 | $879.86K derived: sum of 3 quarters · filed 2026-05-14 | $1.20M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $298.09K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $679.66K derived: sum of 2 quarters · filed 2026-03-27 | $1.00M derived: sum of 3 quarters · filed 2026-08-12 | $1.13M 10-K · filed 2026-03-27 |
| 2025-09-30 | $381.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $703.12K derived: sum of 2 quarters · filed 2026-08-12 | $834.25K 10-Q · filed 2025-11-13 | $901.19K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $321.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $452.68K 10-Q · filed 2026-08-12 | $519.63K derived: sum of 3 quarters · filed 2026-08-12 | $536.16K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $131.13K 10-Q · filed 2026-05-14 | $198.07K derived: sum of 2 quarters · filed 2026-05-14 | $214.61K derived: sum of 3 quarters · filed 2026-05-14 | $224.61K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $66.95K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $83.48K derived: sum of 2 quarters · filed 2026-03-27 | $93.48K derived: sum of 3 quarters · filed 2026-03-27 | $104.22K 10-K · filed 2026-03-27 |
| 2024-09-30 | $16.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $26.54K derived: sum of 2 quarters · filed 2025-11-13 | $37.27K 10-Q · filed 2025-11-13 | $42.60K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $20.74K 10-Q · filed 2025-08-12 | $26.06K derived: sum of 3 quarters · filed 2025-08-12 | $34.27K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $10.74K 10-Q · filed 2025-05-13 | $16.06K derived: sum of 2 quarters · filed 2025-05-13 | $24.27K derived: sum of 3 quarters · filed 2025-05-13 | $40.88K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $5.32K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $13.53K derived: sum of 2 quarters · filed 2025-03-31 | $30.14K derived: sum of 3 quarters · filed 2025-03-31 | $46.97K 10-K · filed 2025-03-31 |
| 2023-09-30 | $8.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $24.82K derived: sum of 2 quarters · filed 2024-11-08 | $41.65K 10-Q · filed 2024-11-08 | $61.29K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $16.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $33.44K 10-Q · filed 2024-08-09 | $53.08K derived: sum of 3 quarters · filed 2024-08-09 | $63.75K derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $16.83K 10-Q · filed 2024-05-09 | $36.47K derived: sum of 2 quarters · filed 2024-05-09 | $47.14K derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | $19.64K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $30.31K derived: sum of 2 quarters · filed 2024-03-28 | $76.63K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $10.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $56.99K 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $46.32K 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |